BAKER BROS. ADVISORS LP Q1 2016 Filing
Filed May 16, 2016
Portfolio Value
$9.5B
Holdings
134
Report Date
Q1 2016
Filing Type
13F-HR
All Holdings (134 positions)
| # | Stock | Shares | Value | % Portfolio | Type |
|---|---|---|---|---|---|
| 1 | INCYIncyte Corporation | 23,498,460 | $1.7T | 17959.44% | |
| 2 | SGENEURSeattle Genetics, Inc. | 43,235,267 | $1.5T | 15999.89% | |
| 3 | ALXNAlexion Pharmaceuticals, Inc. | 6,542,599 | $910.9B | 9606.11% | |
| 4 | ABBVAbbVie Inc. | 14,373,538 | $821.0B | 8658.58% | |
| 5 | ACADACADIA Pharmaceuticals Inc. | 24,213,838 | $677.0B | 7139.97% | |
| 6 | —Incyte Corporation Notes 1.25% 11/15/2020 144A | 274,500,000 | $432.1B | 4557.53% | |
| 7 | —Incyte Corporation Notes 0.375% 11/15/2018 144A | 259,000,000 | $397.9B | 4196.78% | |
| 8 | BMRNBioMarin Pharmaceutical Inc. | 4,806,483 | $396.4B | 4180.92% | |
| 9 | —Genomic Health, Inc. | 13,659,832 | $338.4B | 3568.34% | |
| 10 | —Anacor Pharmaceuticals, Inc. | 5,122,375 | $273.8B | 2887.45% | |
| 11 | —DBV Technologies S.A. | 5,509,560 | $179.3B | 1891.31% | |
| 12 | —Acorda Therapeutics, Inc. | 3,661,082 | $96.8B | 1021.25% | |
| 13 | —BioMarin Pharmaceutical Inc. Notes 1.875% 4/23/2017 | 22,379,000 | $89.8B | 947.31% | |
| 14 | —Clovis Oncology Inc. 2.5% 9/15/2021 | 129,300,000 | $87.8B | 925.97% | |
| 15 | GILD 1.625 05/01/16 DGilead Sciences, Inc. 1.625% 5/1/16 | 20,944,000 | $85.9B | 905.53% | |
| 16 | CERSCerus Corporation | 13,553,275 | $80.4B | 847.61% | |
| 17 | —Anacor Pharmaceuticals Inc. 2.0% 15 OCT 2021 | 42,000,000 | $75.3B | 794.52% | |
| 18 | —Xenoport, Inc. Notes 2.5% 2/1/2022 | 100,000,000 | $73.4B | 774.47% | |
| 19 | MRTXEURMirati Therapeutics, Inc. | 3,268,556 | $69.9B | 737.67% | |
| 20 | —Acorda Therapeutics, Inc. Notes 1.75% 6/15/2021 | 77,083,000 | $68.5B | 721.95% | |
| 21 | —Aquinox Pharmaceuticals, Inc. | 7,752,487 | $68.4B | 721.12% | |
| 22 | NVTA1EURInvitae Corporation | 6,554,967 | $67.1B | 707.20% | |
| 23 | ONCBeiGene, Ltd. | 1,912,680 | $56.1B | 591.23% | |
| 24 | HRTXHeron Therapeutics, Inc. | 2,907,784 | $55.2B | 582.35% | |
| 25 | —Bellicum Pharmaceuticals, Inc. | 4,865,647 | $45.5B | 479.79% | |
| 26 | BCRXBioCryst Pharmaceuticals, Inc. | 15,010,534 | $42.5B | 448.00% | |
| 27 | IMGNEURImmunoGen, Inc. | 4,452,445 | $37.9B | 400.07% | |
| 28 | —Spark Therapeutics, Inc. | 1,262,382 | $37.3B | 392.88% | |
| 29 | NBIXNeurocrine Biosciences, Inc. | 895,422 | $35.4B | 373.48% | |
| 30 | —Versartis, Inc. | 3,199,559 | $25.7B | 270.62% | |
| 31 | GBYSangamo BioSciences, Inc. | 4,055,876 | $24.5B | 258.78% | |
| 32 | —Advanced Accelerator Applications S.A. | 615,033 | $21.5B | 227.14% | |
| 33 | —Exelixis, Inc. Notes 4.25% 8/15/2019 | 20,000,000 | $19.8B | 208.55% | |
| 34 | —Achillion Pharmaceuticals, Inc. | 2,475,515 | $19.1B | 201.55% | |
| 35 | IM8NInsmed Incorporated | 1,500,000 | $19.0B | 200.43% | |
| 36 | —Progenics Pharmaceuticals, Inc. | 4,350,808 | $19.0B | 200.06% | |
| 37 | HALOHalozyme Therapeutics, Inc. | 1,931,057 | $18.3B | 192.86% | |
| 38 | TGTXTG Therapeutics, Inc. | 2,003,991 | $17.1B | 180.07% | |
| 39 | ITCIEURIntra-Cellular Therapies, Inc. | 609,166 | $16.9B | 178.60% | |
| 40 | —XenoPort, Inc. | 3,475,672 | $15.7B | 165.31% | |
| 41 | —Medivation, Inc. | 329,876 | $15.2B | 159.96% | |
| 42 | —bluebird bio, Inc. | 352,943 | $15.0B | 158.19% | |
| 43 | —Foamix Pharmaceuticals Ltd. | 2,241,702 | $14.6B | 154.14% | |
| 44 | —BioMarin Pharmaceutical Inc. Notes 0.75% 10/15/2018 | 12,228,000 | $14.1B | 148.96% | |
| 45 | —Idera Pharmaceuticals, Inc. | 6,990,189 | $13.8B | 145.97% | |
| 46 | —Aegerion Pharmaceuticals, Inc. Notes 2.0% 8/15/2019 | 26,517,000 | $13.5B | 142.65% | |
| 47 | ARRYEURArray BioPharma Inc. | 4,310,666 | $12.7B | 134.11% | |
| 48 | GLPGGalapagos NV | 303,394 | $12.7B | 133.81% | |
| 49 | AGIOAgios Pharmaceuticals, Inc. | 307,915 | $12.5B | 131.84% | |
| 50 | NVAXNovavax, Inc. | 2,379,254 | $12.3B | 129.48% | |
| 51 | —Corsicanto Ltd. 3.5% 1/15/2032 | 15,000,000 | $12.1B | 127.64% | |
| 52 | XNCRXencor, Inc. | 872,072 | $11.7B | 123.42% | |
| 53 | —Derma Sciences, Inc. | 3,752,390 | $11.6B | 122.67% | |
| 54 | OMEROmeros Corporation | 749,250 | $11.5B | 121.21% | |
| 55 | EX9Exelixis, Inc. | 2,580,000 | $10.3B | 108.84% | |
| 56 | —Dimension Therapeutics, Inc. | 1,251,881 | $9.8B | 103.37% | |
| 57 | GBTUSDGlobal Blood Therapeutics, Inc. | 600,000 | $9.5B | 100.36% | |
| 58 | ASNDAscendis Pharma A/S | 505,521 | $9.4B | 98.89% | |
| 59 | —Zogenix, Inc. | 1,000,000 | $9.2B | 97.45% | |
| 60 | —Alcobra Ltd. | 2,336,359 | $8.9B | 93.39% | |
| 61 | ALKSAlkermes plc | 250,251 | $8.6B | 90.23% | |
| 62 | —aTyr Pharma, Inc. | 2,137,606 | $8.4B | 88.82% | |
| 63 | LGNDLigand Pharmaceuticals Incorporated | 73,386 | $7.9B | 82.88% | |
| 64 | RAREUltragenyx Pharmaceutical Inc. | 123,894 | $7.8B | 82.72% | |
| 65 | SG7Sage Therapeutics, Inc. | 224,048 | $7.2B | 75.75% | |
| 66 | MGNXMacroGenics, Inc. | 363,676 | $6.8B | 71.91% | |
| 67 | CNCEEURConcert Pharmaceuticals, Inc. | 495,908 | $6.8B | 71.44% | |
| 68 | PRQRProQR Therapeutics N.V. | 1,349,719 | $6.6B | 69.47% | |
| 69 | CPRXCatalyst Pharmaceuticals, Inc. | 5,498,459 | $6.4B | 67.84% | |
| 70 | —Dermira, Inc. | 275,000 | $5.7B | 59.98% | |
| 71 | —Akari Therapeutics plc | 395,882 | $5.5B | 58.45% | |
| 72 | —Lion Biotechnologies, Inc. | 1,066,285 | $5.4B | 57.13% | |
| 73 | —Endocyte, Inc. | 1,695,865 | $5.3B | 55.44% | |
| 74 | ARWRArrowhead Pharmaceuticals, Inc. | 1,009,509 | $4.9B | 51.32% | |
| 75 | —NeuroDerm Ltd. | 305,000 | $4.3B | 45.42% | |
| 76 | NTRANatera, Inc. | 450,000 | $4.3B | 45.18% | |
| 77 | —Vitae Pharmaceuticals, Inc. | 637,597 | $4.2B | 44.58% | |
| 78 | —Ignyta, Inc. | 571,000 | $3.9B | 40.77% | |
| 79 | —Loxo Oncology, Inc. | 137,735 | $3.8B | 39.72% | |
| 80 | —Trevena, Inc. | 450,000 | $3.7B | 39.25% | |
| 81 | AERIEURAerie Pharmaceuticals, Inc. | 299,356 | $3.6B | 38.39% | |
| 82 | —Aimmune Therapeutics, Inc. | 250,000 | $3.4B | 35.75% | |
| 83 | —Medgenics Inc. | 765,000 | $3.4B | 35.50% | |
| 84 | MCRB1EURSeres Therapeutics, Inc. | 125,000 | $3.3B | 35.01% | |
| 85 | —Curis, Inc. | 1,999,303 | $3.2B | 33.95% | |
| 86 | —Nabriva Therapeutics AG | 350,000 | $3.1B | 33.07% | |
| 87 | —Juno Therapeutics, Inc. | 80,000 | $3.0B | 32.13% | |
| 88 | —Osiris Therapeutics, Inc. | 499,193 | $2.9B | 30.06% | |
| 89 | —Epizyme, Inc. | 232,481 | $2.8B | 29.72% | |
| 90 | —InVivo Therapeutics Holdings Corp. | 400,000 | $2.8B | 29.44% | |
| 91 | QUREuniQure N.V. | 230,000 | $2.7B | 28.81% | |
| 92 | —Adamas Pharmaceuticals, Inc. | 172,630 | $2.5B | 26.32% | |
| 93 | —Sunesis Pharmaceuticals, Inc. | 4,450,000 | $2.4B | 25.34% | |
| 94 | —Array BioPharma Inc. Notes 3.0% 6/1/2020 | 3,000,000 | $2.4B | 25.12% | |
| 95 | —Protalix BioTherapeutics, Inc. Notes 4.5% 9/15/18 | 3,423,000 | $2.3B | 24.61% | |
| 96 | ISIIonis Pharmaceuticals, Inc. | 57,140 | $2.3B | 24.40% | |
| 97 | —Proteon Therapeutics Inc. | 298,591 | $2.3B | 24.37% | |
| 98 | ENTAEnanta Pharmaceuticals, Inc. | 75,357 | $2.2B | 23.34% | |
| 99 | AUPHAurinia Pharmaceuticals Inc. | 711,499 | $2.1B | 21.96% | |
| 100 | TREURTrillium Therapeutics Inc. | 211,792 | $2.0B | 20.66% |
Page 1 of 2Next